Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
Limited Edition Golden Llama is here! Check out how you can get one.
Limited Edition Golden Llama is here! Check out how you can get one.
Offering SPR-BLI Services - Proteins provided for free!
Get your ComboX free sample to test now!
Time Limited Offer: Welcome Gift for New Customers !
Shipping Price Reduction for EU Regions
This protein carries no "tag".
The protein has a calculated MW of 85.5 kDa. The protein migrates as 90-116 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.
>95% as determined by SDS-PAGE.
>95% as determined by SEC-MALS.
Lyophilized from 0.22 μm filtered solution in 50 mM HEPES, 150 mM NaCl, pH7.5 with trehalose as protectant.
Contact us for customized product form or formulation.
Please see Certificate of Analysis for specific instructions.
For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.
For long term storage, the product should be stored at lyophilized state at -20°C or lower.
Please avoid repeated freeze-thaw cycles.
This product is stable after storage at:
Human DPPIV, Tag Free on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95% (With Star Ribbon Pre-stained Protein Marker).
The purity of Human DPPIV, Tag Free (Cat. No. DP4-H5211) is more than 95% and the molecular weight of this protein is around 190-220 kDa verified by SEC-MALS.
Measured by its ability to cleave the fluorogenic peptide substrate, Gly-Pro-7-amido-4-methylcoumarin (GP-AMC). The specific activity is >11000 pmol/min/µg (QC tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides innovative solutions for neuroscience research. Recombinant proteins, neural factors, pre-formed fibrils, electrophysiological electrodes, as well as Organoid Toolbox all in Aneuro aiming to advance neuroscience research, develop therapeutic interventions, and improve diagnostic methods for neurological diseases.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Fecha | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Gemigliptin L-tartrate Sesquihydrate | LC-150444; LC-15-0444 | Approved | Lg Life Sciences Ltd | Gemiglo, Zemiglo | South Korea | Diabetes Mellitus, Type 2 | Lg Life Sciences Ltd | 2012-06-27 | Diabetes Mellitus, Type 2; Hepatic Insufficiency | Details |
Gemigliptin L-tartrate Sesquihydrate/Metformin Hydrochloride | Approved | Lg Life Sciences Ltd | ZemiMet SR | South Korea | Diabetes Mellitus, Type 2 | Lg Life Sciences Ltd | 2015-01-01 | Diabetes Mellitus, Type 2 | Details | |
Teneligliptin Hydrobromide Hydrate/Metformin Hydrochloride | Approved | Handok Inc | Tenelia M SR | South Korea | Diabetes Mellitus, Type 2 | Handok Inc | 2015-11-03 | Diabetes Mellitus, Type 2 | Details | |
Evogliptin | DA-1229 | Approved | Dong-A Pharmaceutical Co Ltd | Suganon, Sugarnon | South Korea | Diabetes Mellitus, Type 2 | Dong-A Pharmaceutical Co Ltd | 2015-10-02 | Diabetes Mellitus, Type 2; Kidney Diseases; Aortic valve diseases; Liver Diseases | Details |
Saxagliptin Hydrate | BMS-477118; BMS-477118-11; OPC-262 | Approved | Bristol-Myers Squibb Company | 安立泽, Onglyza | EU | Diabetes Mellitus, Type 2 | Astrazeneca Ab | 2009-07-31 | Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Hypoglycemia; Diabetes Mellitus | Details |
Teneligliptin Hydrobromide Hydrate | MP-513 | Approved | Mitsubishi Tanabe Pharma | Tenelia, Tenglyn | Japan | Diabetes Mellitus, Type 2 | Mitsubishi Tanabe Pharma, Daiichi Sankyo Co Ltd | 2012-06-29 | Diabetes Mellitus, Type 2 | Details |
Retagliptin Phosphate | SP-2086 Phosphate | Approved | Jiangsu Hengrui Medicine Co Ltd | 瑞泽唐 | Mainland China | Diabetes Mellitus, Type 2 | Jiangsu Hengrui Medicine Co Ltd | 2023-06-27 | Diabetes Mellitus, Type 2; Renal Insufficiency; Diabetes Mellitus | Details |
Sitagliptin Phosphate Monohydrate/Ipragliflozin L-Proline | MK-0431J | Approved | Merck & Co Inc, Astellas Pharma Inc | Sujanu | Japan | Diabetes Mellitus, Type 2 | null | 2018-03-23 | Diabetes Mellitus, Type 2 | Details |
Linagliptin | BI-1356; BI-1356-BS | Approved | Boehringer Ingelheim Gmbh | 欧唐宁, Ondero, Trajenta, Trayenta, Trazenta, Tradjenta | United States | Diabetes Mellitus, Type 2 | Boehringer Ingelheim Gmbh | 2011-05-02 | Prediabetic State; Diabetes Mellitus, Type 2; Albuminuria; Renal Insufficiency; Schizophrenia; Respiratory Tract Diseases; Coronavirus Disease 2019 (COVID-19); Hypertension; Endocrine System Diseases; Coronavirus Infections; Metabolic Diseases; Hepatic Insufficiency; Glucose Metabolism Disorders; Inflammation; Diabetes Mellitus; Ventricular Dysfunction, Left | Details |
Rosuvastatin Calcium/Gemigliptin L-tartrate Sesquihydrate | Approved | Lg Life Sciences Ltd | ZemiStatin | Diabetes Mellitus, Type 2; Dyslipidemias | Details | |||||
Alogliptin Benzoate | SYR-322; TAK-322 | Approved | Takeda | Nesina, 尼欣那, Vipidia | Japan | Diabetes Mellitus, Type 2 | Takeda | 2010-04-06 | Diabetes Mellitus, Type 2; Acute Coronary Syndrome; Diabetes Mellitus | Details |
Empagliflozin/Linagliptin/Metformin | Approved | Boehringer Ingelheim Gmbh, Eli Lilly And Company | Trijardy XR | United States | Diabetes Mellitus, Type 2 | Boehringer Ingelheim Gmbh | 2020-01-27 | Diabetes Mellitus, Type 2 | Details | |
Sitagliptin Phosphate/Metformin Hydrochloride | Approved | Merck & Co Inc | Velmetia, Janumet, 捷诺达, Zituvimet | United States | Diabetes Mellitus, Type 2 | Merck & Co Inc | 2007-03-30 | Diabetes Mellitus, Type 2 | Details | |
Teneligliptin Hydrobromide Hydrate/Canagliflozin Hemihydrate | Approved | Mitsubishi Tanabe Pharma Corp, Daiichi Sankyo Co Ltd | Canalia | Japan | Diabetes Mellitus, Type 2 | Daiichi Sankyo Co Ltd, Mitsubishi Tanabe Pharma | 2017-07-03 | Diabetes Mellitus, Type 2 | Details | |
Anagliptin/Metformin Hydrochloride | SK-1501 | Approved | Sanwa Kagaku Kenkyusho Co Ltd, Suzuken | Metoana | Japan | Diabetes Mellitus, Type 2 | Sanwa Kagaku Kenkyusho Co Ltd | 2018-09-21 | Diabetes Mellitus, Type 2 | Details |
Vildagliptin/Metformin Hydrochloride | LMF-237 | Approved | Novartis Pharma Ag | 宜合瑞, Eucreas, EquMet, Zomarist, Icandra | EU | Diabetes Mellitus, Type 2 | Novartis Europharm Ltd | 2007-11-14 | Diabetes Mellitus, Type 2 | Details |
Alogliptin Benzoate/Metformin Hydrochloride | CT-L01; CT-L-01 | Approved | Takeda Pharmaceutical Co Ltd | Vipdomet, Inisync, Kazano | United States | Diabetes Mellitus, Type 2 | Takeda Pharmaceuticals U.S.A. Inc | 2013-01-25 | Diabetes Mellitus, Type 2 | Details |
Anagliptin | SK-0403; CWP-0403 | Approved | Sanwa Kagaku Kenkyusho Co Ltd | Suiny, Beskoa | Japan | Diabetes Mellitus, Type 2 | null | 2012-09-28 | Diabetes Mellitus, Type 2 | Details |
Dapagliflozin Propanediol Monohydrate/Saxagliptin Hydrochloride | Approved | Astrazeneca Plc | Qtern | EU | Diabetes Mellitus, Type 2 | Astrazeneca Ab | 2016-07-15 | Diabetes Mellitus, Type 2 | Details | |
Alogliptin Benzoate/Pioglitazone Hydrochloride | SYR-322-4833 BL | Approved | Takeda Pharmaceutical Co Ltd | Nesinaact, Oseni, Liovel, Incresync | Japan | Diabetes Mellitus, Type 2 | Takeda | 2011-07-01 | Diabetes Mellitus, Type 2 | Details |
Sitagliptin Phosphate Monohydrate | ONO-5435A; ONO-5435; MK-0431; MK-431; L-000224715 | Approved | Merck Sharp & Dohme Corp | Ristaben, Xelevia, Tesavel, Glactiv, 捷诺维, Januvia, DIABIT-IS X | United States | Diabetes Mellitus, Type 2 | Merck & Co Inc | 2006-10-16 | Gastroparesis; Carcinoma, Hepatocellular; Hyperlipidemias; Kidney Failure, Chronic; Diabetes Mellitus; Inflammation; Lymphoma, Non-Hodgkin; Leukemia, Myeloid, Acute; Renal Insufficiency, Chronic; Cardiovascular Diseases; Hepatic Insufficiency; Hepatitis C; Psoriasis; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Cystic Fibrosis; Insulin Resistance; Coronavirus Disease 2019 (COVID-19); Myelodysplastic Syndromes; Graft vs Host Disease; Glucose Intolerance; Atherosclerosis; Metabolic Dysfunction-Associated Steatotic Liver Disease; Diabetes Mellitus, Type 2; Heart Failure; HIV Infections; Prediabetic State; Diabetes Mellitus, Type 1; Leukemia, Myelogenous, Chronic | Details |
Trelagliptin Succinate | TAK-472; SYR-472; SYR-111472; SYR-111472 succinate | Approved | Takeda Pharmaceutical Co Ltd | Zafatek | Japan | Diabetes Mellitus, Type 2 | Takeda | 2015-03-26 | Diabetes Mellitus, Type 2; Diabetes Mellitus | Details |
Evogliptin Tartrate/Metformin Hydrochloride | DA-1229_01 | Approved | Dong-A Pharmaceutical Co Ltd | Sugamet XR | South Korea | Diabetes Mellitus, Type 2 | Dong-A Pharmaceutical Co Ltd | 2015-12-01 | Diabetes Mellitus, Type 2 | Details |
Sitagliptin/Ertugliflozin | Approved | Pfizer Inc | Steglujan | United States | Diabetes Mellitus, Type 2 | Merck & Co Inc | 2017-12-19 | Diabetes Mellitus, Type 2 | Details | |
Omarigliptin | MK-3102 | Approved | Merck & Co Inc | Marizev | Japan | Diabetes Mellitus, Type 2 | Merck Sharp & Dohme Corp | 2015-09-28 | Diabetes Mellitus, Type 2; Renal Insufficiency, Chronic; Diabetes Mellitus | Details |
Teneligliptin/Pioglitazone | Approved | Glenmark Pharmaceuticals Ltd | Zita Plus Pio | India | Diabetes Mellitus, Type 2 | Glenmark Pharmaceuticals Ltd | 2022-04-25 | Diabetes Mellitus, Type 2 | Details | |
Metformin Hydrochloride/Sitagliptin Hydrochloride | Approved | Sandoz Bv | EU | Sandoz Bv | 2019-12-10 | Diabetes Mellitus, Type 2 | Details | |||
Sitagliptin Tartrate | Approved | Heumann Pharma GmbH & Co Generica KG | Sitagliptin Heumann 25 mg Filmtabletten | EU | Heumann Pharma GmbH & Co Generica KG | 2020-12-14 | Diabetes Mellitus, Type 1; Parkinson Disease; Diabetic Nephropathies | Details | ||
Sitagliptin Hydrochloride | Approved | Laboratorios Alter Sa | Spain | Diabetes Mellitus, Type 2 | Laboratorios Alter Sa | 2019-03-06 | Diabetes Mellitus, Type 2; Polycystic Ovary Syndrome | Details | ||
Gemigliptin | Approved | Details | ||||||||
Linagliptin/Metformin Hydrochloride | GC2129A; GC-2129-A; DW6013 | Approved | Boehringer Ingelheim Gmbh | Jentadueto Xr, Trajenta Duo, Jentadueto, 欧双宁 | United States | Diabetes Mellitus, Type 2 | Boehringer Ingelheim Gmbh | 2012-01-30 | Diabetes Mellitus, Type 2 | Details |
Linagliptin/Empagliflozin | BI 1356/BI 10773; BI 10773/linagliptin; BI 1356/empagliflozin; Empagliflozin/BI 1356; Linagliptin/BI 10773; BI 10773/BI 1356 | Approved | C.H. Boehringer Sohn Ag & Co. Kg | Tradiance, Glyxambi, Esgliteo | United States | Diabetes Mellitus, Type 2 | Boehringer Ingelheim Gmbh | 2015-01-30 | Diabetes Mellitus, Type 2; Cardiovascular Diseases | Details |
Vildagliptin | LAF-237; DSP-7238; LAF-237A; NVP-LAF-237 | Approved | Novartis Pharma Ag | 佳维乐, Equa, Jalra, Galvus, Gliptus, Xiliarx | EU | Diabetes Mellitus, Type 2 | Novartis Europharm Ltd | 2007-09-25 | Prediabetic State; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Renal Insufficiency; Schizophrenia; Kidney Diseases; Insulin Resistance; Dyslipidemias; Diabetes, Gestational; Diabetes Mellitus | Details |
Saxagliptin Hydrochloride/Metformin Hydrochloride | Approved | Astrazeneca Plc | 安立格, Kombiglyze Xr, Komboglyze | EU | Diabetes Mellitus, Type 2 | Astrazeneca Ab | 2010-11-05 | Diabetes Mellitus, Type 2 | Details |
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Dutogliptin Tartrate | REC-01; PHX-1149; PHX-1149T | Phase 3 Clinical | Phenomix | ST Elevation Myocardial Infarction; Myocardial Infarction; Diabetes Mellitus, Type 2; Kidney Diseases; Leukemia, Myeloid, Acute | Details |
Yogliptin | Phase 3 Clinical | Sichuan Sunheal Pharmaceutical Co Ltd, Chengdu Easton Biopharmaceuticals Co Ltd | Diabetes Mellitus, Type 2 | Details | |
CPL2009-0031 | Phase 3 Clinical | Cadila Healthcare Ltd | Diabetes Mellitus, Type 2 | Details | |
Dapagliflozin formate/Linagliptin | IN-C009; AJU-A51 | Phase 3 Clinical | HK inno.N Corporation, Aju Pharm Co Ltd | Diabetes Mellitus, Type 2 | Details |
DA5221-B2 | DA5221-B2 | Phase 3 Clinical | Dong-A ST Co Ltd | Diabetes Mellitus, Type 2 | Details |
LID104 | LID104; LID-104 | Phase 3 Clinical | Ems | Diabetes Mellitus, Type 2 | Details |
TOTUM•63 | TOTUM-63 | Phase 3 Clinical | Valbiotis | Diabetes Mellitus, Type 2 | Details |
Dapagliflozin/Sitagliptin | SID-1903; DW-6012 | Phase 3 Clinical | Astrazeneca Sa | Myocardial Infarction; ST Elevation Myocardial Infarction; Diabetes Mellitus, Type 2 | Details |
Talabostat | PT-100; BXCL-701 | Phase 2 Clinical | Point Therapeutics | Neuroblastoma; Adenocarcinoma; Melanoma; Carcinoma, Non-Small-Cell Lung; Neoplasm Metastasis; Leukemia, Lymphocytic, Chronic, B-Cell; Neoplasms, Germ Cell and Embryonal; Carcinoma, Small Cell; Carcinoma, Pancreatic Ductal; Lung Neoplasms; Leukemia, Myeloid, Acute; Prostatic Neoplasms; Liver Neoplasms; Brain Neoplasms; Sarcoma; Neuroendocrine Tumors; Central Nervous System Neoplasms; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Skin Neoplasms; Myelodysplastic Syndromes; Kidney Neoplasms; Solid tumours; Ovarian Neoplasms | Details |
TQ-F3083 | TQ-F3083; CT-383 | Phase 2 Clinical | Beijing Centaurus Biopharma Co Ltd, Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2; Diabetes Mellitus | Details |
Begelomab | SAND-26; BT 5/9 | Phase 2 Clinical | Adienne | Dermatomyositis; Graft vs Host Disease | Details |
YS-110 | YSCMA; YS-110 | Phase 2 Clinical | Y'S Therapeutics Inc | Mesothelioma | Details |
Singletine | DC-291407; DC-407; DC291407 | Phase 2 Clinical | Cisen Pharmaceutical Co Ltd, Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences | Diabetes Mellitus, Type 2; Fatty Liver | Details |
Metformin/Dapagliflozin/Sitagliptin | GMRx4 | Phase 2 Clinical | George Medicines PTY Ltd, George Medicines UK Ltd | Diabetes Mellitus, Type 2 | Details |
Bogliptin maleate | HL012MA | Phase 2 Clinical | Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences, East China University Of Science And Technology, Shandong Baiji Dichang Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details |
Augliptin Hydrochloride | Phase 1 Clinical | Shanghai Sun-Sail Pharmaceutical Science & Technology Co Ltd, Nanjing Changao Pharmaceutical Science And Technologyco Ltd | Diabetes Mellitus, Type 2 | Details | |
Evogliptin Tartrate | LY-05007 | Phase 1 Clinical | Dong-A Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details |
TQ-05510 | TQ-05510 | Phase 1 Clinical | Jiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd, Beijing Centaurus Biopharma Co Ltd | Diabetes Mellitus, Type 2 | Details |
Lobeglitazone/Sitagliptin | CKD-396 | Phase 1 Clinical | Chong Kun Dang Pharmaceutical Corp | Diabetes Mellitus, Type 2 | Details |
Sitagliptin/Telmisartan | HDDO-16091 + HDDO-16092; HOB-077; HDDO-1609 | Phase 1 Clinical | Hyundai Pharmaceutical Co Ltd | Hypertension; Diabetes Mellitus | Details |
TSL-0319 | TSL-0319 | Phase 1 Clinical | Jiangsu Tasly Diyi Pharmaceutical Co Ltd | Diabetes Mellitus, Type 2 | Details |
Linagliptin/Fimasartan Potassium Trihydrate | Phase 1 Clinical | Boryung Pharmaceutical Co Ltd | Hypertension; Diabetes Mellitus | Details | |
Retagliptin Phosphate/Metformin Hydrochloride | HRX-0701 | Phase 1 Clinical | Jiangsu Hengrui Medicine Co Ltd | Diabetes Mellitus, Type 2 | Details |
CGT-2201 | CGT-2201 | Phase 1 Clinical | Cgenetech(Suzhou China) Co Ltd | Diabetes Mellitus, Type 2; Diabetes Mellitus | Details |
Empagliflozin/Metformin/Sitagliptin (Chong Kun Dang Pharmaceutical) | CKD-379 | Phase 1 Clinical | Chong Kun Dang Pharmaceutical Corp | Diabetes Mellitus, Type 2 | Details |
Empagliflozin/Metformin/Sitagliptin (Overseas Pharmaceuticals) | Phase 1 Clinical | Taizhou Overseas Pharmaceuticals Co Ltd | Diabetes Mellitus, Type 2 | Details | |
THDBH-100 | THDBH100; THDBH101 | Phase 1 Clinical | Wuxi Apptec(Shanghai) Co Ltd | Diabetes Mellitus, Type 2 | Details |
WXSHC-071 | WXSHC-071 | Phase 1 Clinical | Dongbao Zixing (Hangzhou) Biological Medicine Co Ltd | Diabetes Mellitus, Type 2 | Details |
REC-04 | Clinical | Recardio Inc | Cardiovascular Diseases | Details | |
Dutogliptin Tartrate/Metformin Hydrochloride | Phenomix Corporation | Details |
This web search service is supported by Google Inc.